Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms

Morgan, Celia J. A.; Page, Emma; Schaefer, Carola; Chatten, Katharine; Manocha, Amod; Gulati, Sumit; Curran, H. Valerie; Brandner, Brigitta; Leweke, F. Markus

doi:10.1192/bjp.bp.112.121178

Cited by 85 publications

(61 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, limited information is currently available on endocannabinoid and NAE levels in the CSF from healthy humans or patients. Previous studies have quantified the endocannabinoids, 2-AG and AEA (18)(19)(20)(21), and two NAEs (OEA and PEA) (22)(23)(24), but not the related lipid messengers.…”

Section: Preparation Of Standards and Internal Standardsmentioning

confidence: 99%

Quantitative profiling of endocannabinoids and related N-acylethanolamines in human CSF using nano LC-MS/MS

Kantae

Ogino

Noga

et al. 2017

Journal of Lipid Research

View full text Add to dashboard Cite

The endocannabinoid system has emerged as a crucial regulator of synaptic communication in the CNS (1-3). Dysregulation of this system is implicated in various neurological and psychiatric disorders, such as neuroinflammation, stroke, brain trauma, anxiety, and depression (4-8). The endocannabinoid system consists of endogenous lipid messengers (endocannabinoids) that activate two distinct cannabinoid (CB) (CB 1 and CB 2 ) receptors and the en-

show abstract

Section: Preparation Of Standards and Internal Standardsmentioning

confidence: 99%

Quantitative profiling of endocannabinoids and related N-acylethanolamines in human CSF using nano LC-MS/MS

Kantae

Ogino

Noga

et al. 2017

Journal of Lipid Research

View full text Add to dashboard Cite

show abstract

“…In contrast, heavy cannabis use in controls is associated with lower CSF anandamide levels [37]. In comorbid patients, both increased anandamide levels (substance-using patients, including cannabis) [38] and decreased anandamide levels (cannabis-using patients) [39] compared with controls and non-using patients, have been reported.…”

Section: Neurobiology Of the Ecb Systemmentioning

confidence: 98%

Neurobiology of Comorbid Substance Use Disorders in Mental Illness: A Closer Look at the Underlying Commonalities between Cannabis and Schizophrenia

et al. 2014

View full text Add to dashboard Cite

The high rate of cannabis use disorders (CUDs) among patients with schizophrenia is well established. The implications of this comorbidity are extensive and include symptom exacerbation, frequent relapses leading to hospitalization and an overall worsening of prognosis. Therefore, a greater understanding of why cannabis use and schizophrenia frequently present in the same individual is critical. In this article, we propose that common neurobiological pathways and substrates independently contribute to the predisposition of developing these disorders. Dysregulation of the endocannabinoid system, as well as abnormalities in neurophysiology, neurocognition, genetics, and brain morphology may contribute to this comorbidity. Future studies are needed to confirm these commonalities between CUDs and schizophrenia, given that better understanding of their etiology may guide integrated treatment interventions and the development of prevention strategies for these prevalent comorbid disorders.

show abstract

“…People with schizophrenia and a history of chronic cannabis use do not have elevation in CSF anandamide levels [61], suggesting that cannabis use may suppress the brain's natural ability to temper a psychotic process, and pointing towards a potential biological mechanism underlying the cannabis-psychosis link in vulnerable individuals. In healthy volunteers who regularly use cannabis, CSF anandamide levels are decreased and 2-AG levels are increased compared with infrequent cannabis users [62]. In addition, amongst cannabis users, CSF anandamide levels are inversely correlated with persisting psychotic symptoms when cannabis-free, and higher CSF anandamide levels are associated with a lower risk of psychotic symptoms acutely following cannabis use [62].…”

Section: The Ecs and Psychosismentioning

confidence: 99%

“…In healthy volunteers who regularly use cannabis, CSF anandamide levels are decreased and 2-AG levels are increased compared with infrequent cannabis users [62]. In addition, amongst cannabis users, CSF anandamide levels are inversely correlated with persisting psychotic symptoms when cannabis-free, and higher CSF anandamide levels are associated with a lower risk of psychotic symptoms acutely following cannabis use [62].…”

Section: The Ecs and Psychosismentioning

confidence: 99%

Cannabinoids and Schizophrenia: Risks and Therapeutic Potential

Manseau

Goff

2015

Neurotherapeutics

View full text Add to dashboard Cite

A convergence of evidence shows that use of Cannabis sativa is associated with increased risk of developing psychotic disorders, including schizophrenia, and earlier age at which psychotic symptoms first manifest. Cannabis exposure during adolescence is most strongly associated with the onset of psychosis amongst those who are particularly vulnerable, such as those who have been exposed to child abuse and those with family histories of schizophrenia. Schizophrenia that develops after cannabis use may have a unique clinical phenotype, and several genetic polymorphisms may modulate the relationship between cannabis use and psychosis. The endocannabinoid system has been implicated in psychosis both related and unrelated to cannabis exposure, and studying this system holds potential to increase understanding of the pathophysiology of schizophrenia. Anandamide signaling in the central nervous system may be particularly important. Δ 9 -Tetrahydrocannabinol in cannabis can cause symptoms of schizophrenia when acutely administered, and cannabidiol (CBD), another compound in cannabis, can counter many of these effects. CBD may have therapeutic potential for the treatment of psychosis following cannabis use, as well as schizophrenia, possibly with better tolerability than current antipsychotic treatments. CBD may also have antiinflammatory and neuroprotective properties. Establishing the role of CBD and other CBD-based compounds in treating psychotic disorders will require further human research.

show abstract

Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms

Cited by 85 publications

References 10 publications

Quantitative profiling of endocannabinoids and related N-acylethanolamines in human CSF using nano LC-MS/MS

Quantitative profiling of endocannabinoids and related N-acylethanolamines in human CSF using nano LC-MS/MS

Neurobiology of Comorbid Substance Use Disorders in Mental Illness: A Closer Look at the Underlying Commonalities between Cannabis and Schizophrenia

Cannabinoids and Schizophrenia: Risks and Therapeutic Potential

Contact Info

Product

Resources

About